Search details
1.
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Int J Cancer
; 154(12): 2142-2150, 2024 Jun 15.
Article
in English
| MEDLINE | ID: mdl-38447003
2.
First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Final results of the NEPTUN study.
Int J Cancer
; 153(1): 141-152, 2023 07 01.
Article
in English
| MEDLINE | ID: mdl-36757197
3.
Plasma apolipoprotein M predicts overall survival in metastatic breast cancer patients.
Breast Cancer Res Treat
; 201(3): 571-576, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37490173
4.
Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415).
BMC Cancer
; 23(1): 561, 2023 Jun 19.
Article
in English
| MEDLINE | ID: mdl-37337155
5.
Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.
Eur J Haematol
; 108(2): 133-144, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-34714555
6.
Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).
Int J Cancer
; 147(9): 2493-2502, 2020 11 01.
Article
in English
| MEDLINE | ID: mdl-32339253
7.
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma.
Ann Hematol
; 99(8): 1709-1725, 2020 Aug.
Article
in English
| MEDLINE | ID: mdl-32296915
8.
Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.
Br J Haematol
; 176(5): 770-782, 2017 Mar.
Article
in English
| MEDLINE | ID: mdl-27983764
9.
Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.
Br J Haematol
; 178(1): 61-71, 2017 07.
Article
in English
| MEDLINE | ID: mdl-28382618
10.
Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial.
Haematologica
; 101(11): 1398-1406, 2016 11.
Article
in English
| MEDLINE | ID: mdl-27662018
11.
[18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner.
Eur J Nucl Med Mol Imaging
; 40(1): 34-43, 2013 Jan.
Article
in English
| MEDLINE | ID: mdl-23053327
12.
A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells.
Biochem J
; 445(1): 135-44, 2012 Jul 01.
Article
in English
| MEDLINE | ID: mdl-22509934
13.
Circulating Glypican-4 Is a Predictor of 24-Month Overall Survival in Metastatic Breast Cancer.
Oncol Res Treat
; 46(4): 151-156, 2023.
Article
in English
| MEDLINE | ID: mdl-36750040
14.
Cell-free circulating RAS mutation concentrations significantly impact the survival of metastatic colorectal cancer patients.
J Cancer Res Clin Oncol
; 149(9): 6435-6444, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-36763171
15.
Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice.
Blood
; 116(22): 4600-11, 2010 Nov 25.
Article
in English
| MEDLINE | ID: mdl-20696946
16.
Clonal Evolution in Patients with Hormone Receptor Positive, HER-2 Negative Breast Cancer Treated with Chemotherapy or CDK4/6 Inhibitors.
Oncol Res Treat
; 45(5): 248-253, 2022.
Article
in English
| MEDLINE | ID: mdl-35220309
17.
Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients.
Front Oncol
; 12: 1045995, 2022.
Article
in English
| MEDLINE | ID: mdl-36353562
18.
Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO.
Transl Lung Cancer Res
; 11(10): 2010-2021, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-36386456
19.
Elective Discontinuation of CDK4/6 Inhibitors in Patients with Metastatic Hormone Receptor-Positive, Her-2-Negative Breast Cancer: A Retrospective Single-Center Experience.
Oncol Res Treat
; 44(9): 443-449, 2021.
Article
in English
| MEDLINE | ID: mdl-34350900
20.
First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study.
Cancer Med
; 10(22): 8127-8137, 2021 11.
Article
in English
| MEDLINE | ID: mdl-34668662